TELETRADER News
5/25, 6:31 PM (Source: TeleTrader)
more TeleTrader news

Hydroxychloroquine trials paused by WHO

The World Health Organization's (WHO) Executive Group of the Solidarity Trial "has implemented a temporary pause of the hydroxychloroquine" trials until the data on the drug's effects becomes verified, the agency's Director-General Dr. Tedros Adhanom Ghebreyesus (pictured) announced on Monday.

"On Friday, [medical journal] The Lancet published an observational study on hydroxychloroquine and chloroquine," and the study's authors determined that "a higher mortality rate" can be expected among COVID-19 patients who have received the treatment, Dr. Tedros said.

The Executive Group will "review a comprehensive analysis and critical appraisal of all evidence available globally" regarding the treatment, and "will consider data collected so far in the Solidarity Trial and in particular robust randomized available data, to adequately evaluate the potential benefits and harms from this drug," Dr. Tedros explained, stressing that hydroxychloroquine and chloroquine "are accepted as generally safe" for autoimmune diseases or malaria patients.

Breaking the News / MS